Herpes zoster viral infection after AZD1222 and BNT162b2 coronavirus disease 2019 mRNA vaccines: a case series

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e85-e86. doi: 10.1111/jdv.17720. Epub 2021 Oct 10.

Authors

Affiliations

¹ Dermatology Department, University Hospital of Heraklion, Crete, Greece.
² Department of Surgery II, Witten/Herdecke University, Witten, Germany.
³ 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece.
⁴ Microbiology Department, Medical School of Athens, Athens, Greece.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
ChAdOx1 nCoV-19
Herpes Zoster*
Humans
RNA, Messenger
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines, Synthetic
mRNA Vaccines
ChAdOx1 nCoV-19
BNT162 Vaccine